The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Pavblu aflibercept BiosimilarAdditional monitoring | Amgen Technology (Ireland) UC | Wet Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetes Complications | 🇪🇺 EU 2025-01-30 | Order → |
| Pebrilzo pertuzumab Biosimilar | Biosimilar Collaborations Ireland Limited | Breast Neoplasms | 🇪🇺 EU | Order → |
| Pelgraz Paediatric pegfilgrastim Biosimilar | Accord Healthcare S.L.U. | Neutropenia; Febrile Neutropenia; Cancer | 🇪🇺 EU | Order → |
| Pemetrexed ditromethamine Hospira pemetrexed Generic | Mesothelioma; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU | Order → | |
| Pioglitazone ratio pioglitazone Generic | Ratiopharm GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Pioglitazone ratiopharm pioglitazone Generic | Ratiopharm GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Pioglitazone ratiopharm GmbH pioglitazone Generic | Ratiopharm GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Pioglitazone Teva Generics pioglitazone Generic | Teva Pharma B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Plivensia sirukumab | Janssen-Cilag International NV | Arthritis, Rheumatoid | 🇪🇺 EU | Order → |
| Povofortay povorcitinib | Incyte Biosciences Distribution B.V. | Hidradenitis Suppurativa | 🇪🇺 EU 2026-09-17 | Order → |
| Pristiqs desvenlafaxine | Wyeth Europe Ltd. | 🇪🇺 EU | Order → | |
| Prohippur sodium benzoate Orphan | Lucane Pharma | Urea Cycle Disorders, Inborn; Hyperglycinemia, Nonketotic | 🇪🇺 EU | Order → |
| Puldysa idebenone Orphan | Santhera Pharmaceuticals (Deutschland) GmbH | Muscular Dystrophy, Duchenne | 🇪🇺 EU | Order → |
| Qezzaqar catequentinib Orphan | CATS Consultants GmbH | Sarcoma; Leiomyosarcoma | 🇪🇺 EU 2026-07-23 | Order → |
| Qinprezo vosaroxin | Sunesis Europe Ltd | Leukemia, Myeloid, Acute | 🇪🇺 EU | Order → |
| Qizenday | Medday Pharmaceuticals | Multiple Sclerosis | 🇪🇺 EU | Order → |
| Qsiva phentermine;topiramate | Vivus BV | Obesity | 🇪🇺 EU 2013-02-21 | Order → |
| Radicava edaravone Orphan | Mitsubishi Tanabe Pharma GmbH | Amyotrophic Lateral Sclerosis | 🇪🇺 EU | Order → |
| Raligize | FGK Representative Service GmbH | Uterine Cervical Neoplasms | 🇪🇺 EU | Order → |
| Raltegravir Viatris raltegravir potassium Generic | Viatris Limited | HIV Infections | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.